FINWIRES · TerminalLIVE
FINWIRES

RBC Maintains CAE's Sector Perform Rating and C$42.00 Price Target Ahead of Fiscal Q4 Results

-- RBC Capital Markets maintained its sector perform rating and C$42.00 price target on the shares of CAE (CAE.TO, CAE) on Friday.

RBC expects CAE's upcoming Fiscal Q4 report to shift attention to the company's long-term growth opportunities. It expects management to outline targets for revenue, margins, CapEx, EPS, and ROIC through FY30.

RBC believes secular tailwinds in both Civil and Defense can support 4-5% revenue growth longer-term, with key focus on what level of FCF management's targets imply.

RBC's new FY30 forecasts call for ~100% FCF conversion and EPS of $2.21, it added.

"While we remain Sector Perform into the quarter, we will be looking for colour that gives us increased confidence in execution, which could provide a lift to valuation," said RBC.

RBC believes FY27 will "come in well below street estimates," although RBC does not expect this to be a major focus for investors. It expects FY27 to represent a "transitional year" for CAE as it works through the execution phase of its transformation plan.

"While the strategic initiatives we expect management to lay out could yield meaningful benefits over the medium term, the near-term financial profile will likely reflect the friction of restructuring activities, ongoing market headwinds, and the lag between cost actions and margin realization," added RBC.

RBC expects management to lay out a growth framework underpinned by "strong secular tailwinds" in both Civil and Defense that it believes will support revenue growth of 4-5% annually.

"On the margin front, we expect management to target Civil operating margins of ~25% (vs. ~20% today), reflecting the benefits of network rationalization, improved utilization, and a leaner cost structure; and Defense operating margins of ~11% (vs. ~8.5% today), driven by the continued roll-off of legacy contracts and a higher mix of new, betterpriced programs," said RBC.

RBC expects these revenue and margin improvements to drive capital efficiency gains, with CapEx moderating to ~$300MM longer-term as network right-sizing reduces growth capital requirements. RBC expects this to drive EPS of >$2.00 in FY30.

"We now value CAE off our new F30 EPS estimate of $2.21, applying a 22.5x multiple and discounting back at 8%, which results in our $42 price target," said RBC.

Price: $34.50, Change: $-0.27, Percent Change: -0.78%

相关文章

Insider Trading

根据最近提交给美国证券交易委员会(SEC)的文件显示,高盛集团内部人士出售了价值1,044,782美元的股票。

首席风险官 Alex S Golten 于 2026 年 4 月 23 日出售了 1,116 股高盛集团 (GS) 股票,套现 1,044,782 美元。根据向美国证券交易委员会 (SEC) 提交的 4 号表格文件,Golten 共持有该公司 2,578 股普通股,其中 2,578 股为直接持有。 SEC 文件链接: https://www.sec.gov/Archives/edgar/data/886982/000205084926000015/xslF345X05/wk-form4_1777061036.xml

$GS
Research

研究报告:CFRA 将 West Pharmaceutical Services, Inc. 的评级从“持有”上调至“买入”。

独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们12个月的目标价为350美元,高于此前的267美元,相当于我们2026年每股收益预期的41倍(上调0.63美元至8.53美元;2027年每股收益预期上调0.61美元至9.42美元),接近WST五年远期平均市盈率42倍。我们的估值反映了我们对高价值产品(HVP)业务强劲表现、GLP-1弹性体销售市场增长以及公司稳健的资产负债表(净负债为负)的预期。我们预计新药研发将支撑HVP业务,因为生物制剂在2026年第一季度约占销售额的42%。此外,GLP-1药物的需求可能成为注射器销售的新催化剂。 WST与诺和诺德签订了一份多年期合同,为其所有GLP-1初级包装弹性体需求提供供应。GLP-1弹性体占2026年第一季度销售额的10%。加上West Vantage业务板块的销售额,GLP-1相关业务在该季度占总净销售额的18%。我们认为,医疗器械制造领域附件1法规的更新也为HVP带来了利好,这得益于WST现有组件的质量升级项目。

$WST
Australia

行业动态:能源股午后走软

周五下午晚些时候,能源股下跌,纽约证券交易所能源板块指数下跌0.7%,道富能源精选行业SPDR ETF(XLE)下跌0.2%。 费城石油服务板块指数上涨1.8%,道琼斯美国公用事业指数上涨0.1%。 西德克萨斯中质原油下跌1.2%至每桶94.68美元,全球基准布伦特原油上涨0.5%至每桶105.64美元。亨利枢纽天然气期货下跌3.7%至每百万英热单位2.52美元。 公司新闻方面,道达尔能源(TTE)为其位于哈萨克斯坦东南部的米尔尼陆上风电和电池储能系统项目获得了融资。该公司股价下跌0.7%。 X-Energy(XE)股票在纳斯达克上市首日飙升27%。 斯洛伐克(SLB)公布的第一季度业绩喜忧参半,反映出中东冲突带来的不利影响。由于营收超出预期,但盈利下滑,该公司股价上涨2.8%。 据彭博社报道,西班牙燃料批发商Hatta Energy向欧盟委员会投诉英国石油(BP)和雷普索尔(Repsol)存在反竞争行为。BP股价下跌0.4%。

$BP$SLB$TTE$XE